Forbes Medi-Tech Inc. Provides Update on TSX Listing

VANCOUVER, BRITISH COLUMBIA--(Marketwire - January 14, 2009) - Forbes Medi-Tech Inc. (TSX: FMI)(NASDAQ: FMTI) (“Forbes” or “Company”) announced today that it has received notice from the Toronto Stock Exchange (“TSX”), indicating that the TSX is reviewing the eligibility of Forbes’ common shares for continued listing on the TSX. The delisting review announced by the TSX relates to Forbes’ market capitalization, which has fallen below the designated TSX threshold. Pursuant to the TSX’s Remedial Review Process, Forbes has been given 210 days - until August 12, 2009 - to regain compliance with the TSX continued listing requirements.

About Forbes Medi-Tech

Forbes Medi-Tech Inc. (TSX: FMI)(NASDAQ: FMTI) is a life sciences company focused on evidence-based nutritional solutions. A leader in nutraceutical technology, Forbes is a provider of value-added products and cholesterol-lowering ingredients for use in functional foods and dietary supplements. Forbes successfully developed and commercialized its Reducol™ plant sterol blend, which has undergone clinical trials in various matrices and has been shown to lower “LDL” cholesterol levels safely and naturally. Building upon established partnerships with leading retailers and manufacturers across the globe, Forbes helps its customers to develop private label and branded products. For more information about Forbes Medi-Tech, please visit www.forbesmedi.com.

This News Release contains forward-looking statements and forward-looking information, within the meaning of applicable securities laws (collectively, “forward-looking statements”), regarding the Company’s continued listing on TSX. Forward-looking statements can be identified by forward-looking terminology such as “August 12, 2009", and similar expressions or variations thereon. Forward-looking statements are inherently uncertain, and actual results may differ materially from the forward-looking statements due to a variety of risks, uncertainties and other factors, including, without limitation, uncertainty whether the Company will meet the TSX continued listing requirements by August 12, 2009, failing which, the Company’s securities will be delisted by the TSX; and the risk that delisting of the Company’s securities may have a material adverse effect on the Company’s share liquidity and trading price and on the Company’s ability to obtain financing and continue its business. For a further discussion of these and other known risks and uncertainties affecting the Company and its business, please see our latest Annual Information Form / Form 20-F, and other documents filed by us with Canadian and U.S. securities regulatory authorities at www.sedar.com and www.sec.gov. Forward-looking statements are based on the beliefs, assumptions, and expectations of the Company’s management at the time they are made, and the Company does not assume any obligation, except as required by law, to update its forward-looking statements if those beliefs, assumptions, or expectations or other circumstances should change.

Reducol™ is a trademark of Forbes Medi-Tech Inc.